Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study

Naheema S. Gordon; Laura A. Baxter; Anshita Goel; Roland Arnold; Baljit Kaur; Wenyu Liu; Sarah J. Pirrie; Syed Hussain; Richard Viney; Daniel Ford; Anjali Zarkar; Mary A. Wood; Timur Mitin; Reid F. Thompson; Nicholas D. James; Douglas G. Ward; Richard T. Bryan

doi:10.1111/bju.15589

Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study

Naheema S. Gordon, Laura A. Baxter, Anshita Goel, Roland Arnold, Baljit Kaur, Wenyu Liu, Sarah J. Pirrie, Syed Hussain, Richard Viney, Daniel Ford, Anjali Zarkar, Mary A. Wood, Timur Mitin, Reid F. Thompson, Nicholas D. James, Douglas G. Ward, Richard T. Bryan

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	32-34
Number of pages	3
Journal	BJU international
Volume	129
Issue number	1
DOIs	https://doi.org/10.1111/bju.15589
State	Published - Jan 2022

ASJC Scopus subject areas

Urology

Access to Document

10.1111/bju.15589

Cite this

Gordon, N. S., Baxter, L. A., Goel, A., Arnold, R., Kaur, B., Liu, W., Pirrie, S. J., Hussain, S., Viney, R., Ford, D., Zarkar, A., Wood, M. A., Mitin, T., Thompson, R. F., James, N. D., Ward, D. G., & Bryan, R. T. (2022). Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. BJU international, 129(1), 32-34. https://doi.org/10.1111/bju.15589

Gordon, NS, Baxter, LA, Goel, A, Arnold, R, Kaur, B, Liu, W, Pirrie, SJ, Hussain, S, Viney, R, Ford, D, Zarkar, A, Wood, MA, Mitin, T , Thompson, RF, James, ND, Ward, DG & Bryan, RT 2022, 'Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study', BJU international, vol. 129, no. 1, pp. 32-34. https://doi.org/10.1111/bju.15589

@article{d67e8f31f6084cf59fefe0d5630db0fd,

title = "Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study",

author = "Gordon, {Naheema S.} and Baxter, {Laura A.} and Anshita Goel and Roland Arnold and Baljit Kaur and Wenyu Liu and Pirrie, {Sarah J.} and Syed Hussain and Richard Viney and Daniel Ford and Anjali Zarkar and Wood, {Mary A.} and Timur Mitin and Thompson, {Reid F.} and James, {Nicholas D.} and Ward, {Douglas G.} and Bryan, {Richard T.}",

note = "Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: Timur Mitin: UpToDate, Inc (royalties for chapter authorship), Novocure (study grant and advisory board), AstraZeneca (advisory board). Richard T. Bryan: Olympus Medical Systems (advisory board), Janssen (advisory board), UroGen Pharma (research grant), QED Therapeutics (research grant), Nonacus Limited (advisory board). Douglas G. Ward: Nonacus Limited (advisory board). Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. ",

year = "2022",

month = jan,

doi = "10.1111/bju.15589",

language = "English (US)",

volume = "129",

pages = "32--34",

journal = "BJU international",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer

T2 - a pilot study

AU - Gordon, Naheema S.

AU - Baxter, Laura A.

AU - Goel, Anshita

AU - Arnold, Roland

AU - Kaur, Baljit

AU - Liu, Wenyu

AU - Pirrie, Sarah J.

AU - Hussain, Syed

AU - Viney, Richard

AU - Ford, Daniel

AU - Zarkar, Anjali

AU - Wood, Mary A.

AU - Mitin, Timur

AU - Thompson, Reid F.

AU - James, Nicholas D.

AU - Ward, Douglas G.

AU - Bryan, Richard T.

N1 - Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: Timur Mitin: UpToDate, Inc (royalties for chapter authorship), Novocure (study grant and advisory board), AstraZeneca (advisory board). Richard T. Bryan: Olympus Medical Systems (advisory board), Janssen (advisory board), UroGen Pharma (research grant), QED Therapeutics (research grant), Nonacus Limited (advisory board). Douglas G. Ward: Nonacus Limited (advisory board). Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85115144230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115144230&partnerID=8YFLogxK

U2 - 10.1111/bju.15589

DO - 10.1111/bju.15589

M3 - Article

C2 - 34491610

AN - SCOPUS:85115144230

SN - 1464-4096

VL - 129

SP - 32

EP - 34

JO - BJU international

JF - BJU international

IS - 1

ER -

Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this